Abstract
Novartis AG will report first-quarter 2026 results on April 28, 2026, Pre-Market; this preview summarizes consensus and company-indicated forecasts across revenue, margins, and EPS, and frames the key moving parts heading into the print.
Market Forecast
For the current quarter, the latest forecast set points to revenue of 13.36 billion US dollars, implying 2.29% year-over-year growth, with an estimated EPS of 2.08 and EBIT of 4.75 billion US dollars; year-over-year, the EPS estimate implies a 2.56% decline and EBIT estimate implies a 7.08% decline. Management’s margin trend last quarter provides the most recent reference points: gross profit margin was 74.44% and net profit margin was 17.38%, and these are widely used by the market as baseline anchors for this quarter’s profitability expectations.
The company’s core portfolio continues to be driven by oncology, immunology, cardiovascular-metabolic, neuroscience, and a branded-mature portfolio, with oncology remaining the largest contributor; investors are focused on revenue durability across key growth brands and pipeline catalysts.
Within the portfolio, oncology is expected to be the most promising segment near term given increasing contributions from newer therapies; revenue scale from this segment last quarter was 16.83 billion US dollars on a trailing basis used in segment disclosures.
Last Quarter Review
In the previous quarter, revenue was 13.86 billion US dollars with a gross profit margin of 74.44%, GAAP net profit attributable to shareholders of 2.41 billion US dollars, a net profit margin of 17.38%, and adjusted EPS was not disclosed in the last-quarter actuals field, while the prior-quarter forecast field indicated 2.00 as the reference estimate; year-over-year revenue growth was 5.38%.
A key financial highlight was a solid top-line beat versus the earlier estimate baseline, as the company recorded 13.86 billion US dollars against a prior estimate set of 13.60 billion US dollars. Main business highlights reflected oncology as the largest contributor at 16.83 billion US dollars on the segment breakdown basis, followed by the branded portfolio at 12.46 billion US dollars and immunology at 10.29 billion US dollars, with cardiovascular-metabolic at 8.96 billion US dollars and neuroscience at 5.99 billion US dollars.
Current Quarter Outlook
Main commercial engine
The primary commercial engine is expected to be anchored by the company’s broad specialty portfolio, with consensus bracketing revenue near 13.36 billion US dollars and modest year-over-year growth. Street models embed stable-to-slightly lower margin dynamics versus last year, using last quarter’s 74.44% gross margin and 17.38% net margin as guideposts, which implies a mix of price and volume supports offset by incremental investments and lifecycle pressure in parts of the base business. Given the breadth across therapeutic areas, the print is likely to show resilient demand across established growth brands alongside normal seasonality for the first quarter.
Most promising growth catalyst
Oncology remains positioned as the near-term growth catalyst, supported by continuing uptake of newer therapies and expanded indications within the franchise. Management and external commentary through recent months have emphasized higher peak sales potential for key oncology assets, which, if reflected in quarterly run-rates, can offset pressure in maturing categories. The magnitude of any year-over-year acceleration within oncology will be watched closely relative to the segment’s large base (16.83 billion US dollars reported in the breakdown), as this decides whether mix can support consolidated margin stability.
Key stock-price drivers this quarter
Three variables are most likely to swing the shares around the print. First, the revenue quality mix between higher-margin specialty drugs and the branded-mature portfolio influences gross margin against the 74.44% reference, and even small mix shifts can move EPS given operating leverage. Second, commentary on 2026 operating-profit trajectories and competition from lower-cost alternatives in cardiovascular-metabolic therapy can color forward EBIT expectations, especially since the quarter’s EBIT forecast implies a 7.08% decline year over year. Third, updates on pipeline progress and any commercial inflection for recent launches provide catalysts for revisions to full-year revenue growth, which the market currently frames at low-single-digit for the quarter, while monitoring whether EPS can converge back to flat or slightly positive versus the 2.56% implied decline.
Analyst Opinions
Across recent institutional commentary, opinions skew constructive. Multiple notes have reiterated positive or neutral stances, while outright negative views are in the minority. Counting the latest items within the defined period, Buy/Positive and Hold/Neutral views outnumber negative ratings, producing a majority bullish-to-neutral stance that leans constructive.
Morgan Stanley maintained a Buy rating with a 170.00 US dollars price target, reflecting confidence in the earnings durability of key growth assets and scope for further capital deployment to strengthen the pipeline. Additional institutional commentary highlights continued execution and reaffirmed guidance for 2025, with expectations for high single-digit sales growth and low-teens growth in core operating income for the full year, which underpins the current quarter’s soft-landing profile. Analysts point to oncology and immunology as primary growth vectors in the portfolio, with the performance of leading brands expected to offset lifecycle pressures in other categories. The consensus takeaway is that the quarter should deliver modest top-line growth near 2.29%, with the debate centered on the margin trajectory and whether EPS lands close to the 2.08 forecast. A delivery in line with these benchmarks would support the constructive stance, while upside would likely require evidence of faster oncology growth or lower-than-expected operating expense intensity.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments